NASDAQ: CNTNCanton Strategic Holdings Inc Stock
$4.51-0.23 (-4.85%)
Updated Feb 19, 2026
CNTN Price
$4.51
Fair Value Price
$2.75
Market Cap
$158.05M
52 Week Low
$0.95
52 Week High
$9.08
P/E
-1.13x
P/B
25.68x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$9M
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNTN Overview
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapies for treatment resistant cancers. Its approach targets ferroptosis, an anti-cancer mechanism resulting in iron-mediated cancer cell death. Hillstream BioPharma was incorporated in 2017 and is based in Bridgewater, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNTN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNTN
Ranked#182 of 479
Ranked#182 of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.20 | A | |
| $7.48 | A | |
| $14.40 | A |
Be the first to know about important CNTN news, forecast changes, insider trades & much more!
CNTN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNTN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNTN ($4.51) is overvalued by 64.25% relative to our estimate of its Fair Value price of $2.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CNTN ($4.51) is not significantly undervalued (64.25%) relative to our estimate of its Fair Value price of $2.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CNTN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNTN due diligence checks available for Premium users.
Valuation
CNTN fair value
Fair Value of CNTN stock based on Discounted Cash Flow (DCF)
Price
$4.51
Fair Value
$2.75
Overvalued by
64.25%
CNTN ($4.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNTN ($4.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNTN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNTN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.13x
Industry
200.65x
Market
44.15x
CNTN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
25.68x
Industry
5.18x
CNTN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNTN's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
CNTN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.7M
Liabilities
$1.5M
Debt to equity
0.25
CNTN's short-term assets ($7.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNTN's short-term assets ($7.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNTN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$0.0
Financing
$7.2M
CNTN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNTN vs Biotech Stocks
Canton Strategic Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.